Simon P Fletcher
Overview
Explore the profile of Simon P Fletcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bockmann J, Allweiss L, Volmari A, da Fonseca Araujo D, Kohsar M, Hyrina A, et al.
JHEP Rep
. 2025 Feb;
7(3):101273.
PMID: 39980752
Background & Aims: The role of hepatocytes in producing chemokines and triggering liver inflammation and damage in chronic hepatitis D (CHD) is not fully understood. Herein, we investigated the contribution...
2.
Fletcher S, Beran R
Viruses
. 2024 Nov;
16(11).
PMID: 39599907
Chronic hepatitis B (CHB) affects approximately 300 million people worldwide and current therapies rarely cure it [...].
3.
Gu S, Tang L, Guo L, Zhong C, Fu X, Ye G, et al.
Emerg Microbes Infect
. 2024 Oct;
13(1):2409350.
PMID: 39470771
It is well established that humoral immunity targeting hepatitis B virus surface antigen (HBsAg) plays a critical role in viral clearance and clinical cure. However, the functional changes in HBsAg-specific...
4.
Pan D, Soulette C, Aggarwal A, Han D, van Buuren N, Wu P, et al.
Gut
. 2024 Oct;
74(4):628-638.
PMID: 39384203
Background: The impact of nucleos(t)ide analogues on intrahepatic viral burden and immune microenvironment in patients with chronic hepatitis B (CHB) is not clear. Objective: We aimed to characterise the effects...
5.
Yu M, Dandri M, Cheng G, Delaney 4th W, Fletcher S, Allweiss L
Methods Mol Biol
. 2024 Jul;
2837:113-124.
PMID: 39044079
HBV covalently closed circular DNA (cccDNA) plays an important role in the persistence of hepatitis B virus (HBV) infection by serving as the template for transcription of viral RNAs. To...
6.
Vecchi A, Rossi M, Tiezzi C, Fisicaro P, Doselli S, Gabor E, et al.
Gut
. 2024 Jul;
73(10):1737-1748.
PMID: 39033025
Objective: Selected populations of patients with chronic hepatitis B (CHB) may benefit from a combined use of pegylated interferon-alpha (pegIFN-α) and nucleos(t)ides (NUCs). The aim of our study was to...
7.
Kornyeyev D, Song Z, Eng S, Soulette C, Ramirez R, Tang J, et al.
Antimicrob Agents Chemother
. 2024 May;
68(7):e0042024.
PMID: 38780261
Capsid assembly mediated by hepatitis B virus (HBV) core protein (HBc) is an essential part of the HBV replication cycle, which is the target for different classes of capsid assembly...
8.
Roca Suarez A, Plissonnier M, Grand X, Michelet M, Giraud G, Saez-Palma M, et al.
Gut
. 2024 May;
73(12):2012-2022.
PMID: 38697771
Objective: Achieving HBV cure will require novel combination therapies of direct-acting antivirals and immunomodulatory agents. In this context, the toll-like receptor 8 (TLR8) agonist selgantolimod (SLGN) has been investigated in...
9.
Janssen H, Lim Y, Kim H, Sowah L, Tseng C, Coffin C, et al.
JHEP Rep
. 2024 Jan;
6(2):100975.
PMID: 38274492
Background & Aims: Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated...
10.
Gane E, Dunbar P, Brooks A, Zhang F, Chen D, Wallin J, et al.
J Hepatol
. 2023 Dec;
78(3):513-523.
PMID: 38133554
Background & Aims: Selgantolimod (GS-9688) is a Toll-like receptor 8 (TLR8) agonist that suppresses HBV in vitro. In a phase II study, we evaluated the safety and efficacy of weekly...